Přejít k obsahu
Merck
Všechny fotografie(2)

Hlavní dokumenty

Zobrazit celou dokumentaci

A3160

Sigma-Aldrich

Acetylsalicylic acid

analytical standard

Synonyma:

2-Acetoxybenzoic acid, O-Acetylsalicylic acid, ASA, Aspirin

Přihlásitk zobrazení cen stanovených pro organizaci a smluvních cen
Všechny fotografie(2)

About This Item

Lineární vzorec:
2-(CH3CO2)C6H4CO2H
Číslo CAS:
50-78-2
Molekulová hmotnost:
180.16
Beilstein/REAXYS Number:
779271
EC Number:
200-064-1
MDL number:
MFCD00002430
UNSPSC Code:
12352106
PubChem Substance ID:
24890723
NACRES:
NA.21

grade

analytical standard

Quality Level

200

form

powder

packaging

vial of 500 mg

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

mp

134-136 °C (lit.)

application(s)

forensics and toxicology
pharmaceutical
veterinary

SMILES string

CC(=O)Oc1ccccc1C(O)=O

InChI

1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)

InChI key

BSYNRYMUTXBXSQ-UHFFFAOYSA-N

Gene Information

human ... ITGA2B(3674) , PTGS1(5742) , PTGS2(5743)

Hledáte podobné produkty? Navštivte Průvodce porovnáváním produktů

Biochem/physiol Actions

Blocks the production of prostaglandins by inhibiting cyclooxygenase (prostaglandin H synthase), with greater selectivity toward the COX-1 isoform. The antithrombotic effect is due to the inhibition of COX-1 in platelets that blocks thromboxane production and platelet aggregation. Chemopreventive against colorectal and other solid tumors.

Packaging

Supplied in amber screw-cap vials

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk_germany

WGK 1

flash_point_f

482.0 °F

flash_point_c

250 °C

ppe

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

Vyberte jednu z posledních verzí:

Osvědčení o analýze (COA)

Lot/Batch Number
0000398362
SLCQ5262
0000398362
0000342719
SLCG8819

Nevidíte správnou verzi?

Potřebujete-li konkrétní verzi, můžete vyhledat daný certifikát podle čísla dávky nebo čísla šarže.

Vyhledat COA

Již tento produkt vlastníte?

Dokumenty související s produkty, které jste v minulosti zakoupili, byly za účelem usnadnění shromážděny ve vaší Knihovně dokumentů.

Navštívit knihovnu dokumentů

Zákazníci si také prohlíželi

Slide 1 of 5

1 of 5

Aspirin meets USP testing specifications

Sigma-Aldrich

A2093

Aspirin

Acetanilide zone-refined, purified by sublimation, ≥99.95%

Sigma-Aldrich

397237

Acetanilide

Caffeine Sigma Reference Standard, vial of 250 mg

Sigma-Aldrich

C1778

Caffeine

Sucrose BioUltra, for molecular biology, ≥99.5% (HPLC)

Sigma-Aldrich

84097

Sucrose

Acetylsalicylic acid-α-13C 99 atom % 13C

Sigma-Aldrich

603287

Acetylsalicylic acid-α-13C

Connie N Hess et al.
Journal of the American College of Cardiology, 66(7), 777-787 (2015-08-14)
Bleeding limits anticoagulant treatment in patients with acute coronary syndromes (ACS). We investigated whether background concomitant antiplatelet therapy influences the effects of apixaban after ACS. This study examined high-risk ACS patients who were treated with aspirin or aspirin plus clopidogrel
Niels Hulsman et al.
Journal of medicinal chemistry, 50(10), 2424-2431 (2007-04-20)
Hybrid drug 1 (NO-ASA) continues to attract intense research from chemists and biologists alike. It consists of ASA and a -ONO2 group connected through a spacer and is in preclinical development as an antitumor drug. We report that, contrary to
A O Maree et al.
Journal of thrombosis and haemostasis : JTH, 3(10), 2340-2345 (2005-09-10)
Aspirin (acetylsalicylic acid) irreversibly inhibits platelet cyclooxygenase (COX)-1, the enzyme that converts arachidonic acid (AA) to the potent platelet agonist thromboxane (TX) A2. Despite clear benefit from aspirin in patients with cardiovascular disease (CAD), evidence of heterogeneity in the way
Gregg W Stone et al.
Lancet (London, England), 382(9892), 614-623 (2013-07-31)
The relation between platelet reactivity and stent thrombosis, major bleeding, and other adverse events after coronary artery implantation of drug-eluting stents has been incompletely characterised. We aimed to determine the relation between platelet reactivity during dual therapy with aspirin and
Andrew O Maree et al.
Journal of the American College of Cardiology, 46(7), 1258-1263 (2005-10-04)
We investigated whether use of low-dose enteric-coated (EC) aspirin for secondary prevention of cardiovascular events has sufficient bioavailability to achieve complete platelet cyclooxygenase (COX) inhibition in all individuals. Aspirin reduces cardiovascular morbidity and mortality in patients with pre-existing vascular disease;
Zobrazit všechny související dokumenty

Náš tým vědeckých pracovníků má zkušenosti ve všech oblastech výzkumu, včetně přírodních věd, materiálových věd, chemické syntézy, chromatografie, analytiky a mnoha dalších..

Obraťte se na technický servis.